Hypertension
Conditions
Interventions
Experimental group:Conventional treatment and sacubitrilvalsartan
Ctrol group:Conventional treatment and antihypertensive drugs
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 50 to 80 years; 2. The history of hypertension; 3. NT-proBNP >= 125pg/ml with sinus rhythm or NT-proBNP >=375 pg/ml with atrial fibrillation; 4. No history of heart failure; 5. Willing to sign informed consent.
Exclusion criteria
Exclusion criteria: 1.History of heart failure or diagnosis; 2.History of malignant tumor; 3.History of chronic infectious diseases; 4.Use hormone therapy for systemic diseases; 5.Severe liver and kidney dysfunction (including renal replacement therapy); 6.Combined with hyperkalemia (serum potassium>5.4mmol/L); 7.Severe cognitive dysfunction or dementia; 8.The life expectancy is less than 1 year; 9.Sacubitrilvalsartan are being used; 10.Angioedema occurred after taking RAS inhibitors; 11.Combined with renal artery stenosis; 12.Women in pregnancy;13.Participating in other interventional research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change of N-terminal natriuretic peptide precursor; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure;Vascular endothelial function;Echocardiography;Microalbuminuria; | — |
Countries
China
Contacts
Public ContactZhou Jingmin
Zhongshan Hospital, Fudan University
Outcome results
None listed